Search research articles
Contact Us
Filters
Showing results (1011-1020 of 1,873) with videos related to
Page
of 188
Sort By:
Circulation. Heart Failure
|
January 21, 2020
Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study
Peder L Myhre, Muthiah Vaduganathan, Eileen O'Meara, et al.
ESC Heart Failure
|
October 20, 2020
Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HF
Su E Yeoh, Pooja Dewan, Akshay S Desai, et al.
Clinical Chemistry
|
January 8, 2021
High-Sensitivity Cardiac Troponin, Natriuretic Peptide, and Long-Term Risk of Acute Kidney Injury: The Atherosclerosis Risk in Communities (ARIC) Study
Junichi Ishigami, Yuhree Kim, Yingying Sang, et al.
JAMA Cardiology
|
December 8, 2022
Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial
Luis E Rohde, André Zimerman, Muthiah Vaduganathan, et al.
European Heart Journal
|
November 27, 2020
Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study
Jörg Täubel, Wilfried Hauke, Steffen Rump, et al.
JACC. Heart Failure
|
April 1, 2017
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial
Inder S Anand, Brian Claggett, Jiankang Liu, et al.
Journal of the American College of Cardiology
|
April 15, 2014
Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease
Jacob A Udell, David A Morrow, Petr Jarolim, et al.
Circulation. Heart Failure
|
February 5, 2015
Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial
Carine E Hamo, John F Heitner, Marc A Pfeffer, et al.
JACC. Heart Failure
|
September 13, 2020
Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis
Luis E Rohde, Neal A Chatterjee, Muthiah Vaduganathan, et al.
JAMA
|
May 29, 2024
Revisiting Race and the Benefit of RAS Blockade in Heart Failure: A Meta-Analysis of Randomized Clinical Trials
Li Shen, Matthew M Y Lee, Pardeep S Jhund, et al.
Page
of 188
Search research articles
Search
Showing results (1011-1020 of 1,873) with videos related to
Sort By:
Page
of 188
Circulation. Heart Failure
|
January 21, 2020
Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study
Peder L Myhre, Muthiah Vaduganathan, Eileen O'Meara, et al.
ESC Heart Failure
|
October 20, 2020
Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HF
Su E Yeoh, Pooja Dewan, Akshay S Desai, et al.
Clinical Chemistry
|
January 8, 2021
High-Sensitivity Cardiac Troponin, Natriuretic Peptide, and Long-Term Risk of Acute Kidney Injury: The Atherosclerosis Risk in Communities (ARIC) Study
Junichi Ishigami, Yuhree Kim, Yingying Sang, et al.
JAMA Cardiology
|
December 8, 2022
Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial
Luis E Rohde, André Zimerman, Muthiah Vaduganathan, et al.
European Heart Journal
|
November 27, 2020
Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study
Jörg Täubel, Wilfried Hauke, Steffen Rump, et al.
JACC. Heart Failure
|
April 1, 2017
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial
Inder S Anand, Brian Claggett, Jiankang Liu, et al.
Journal of the American College of Cardiology
|
April 15, 2014
Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease
Jacob A Udell, David A Morrow, Petr Jarolim, et al.
Circulation. Heart Failure
|
February 5, 2015
Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial
Carine E Hamo, John F Heitner, Marc A Pfeffer, et al.
JACC. Heart Failure
|
September 13, 2020
Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis
Luis E Rohde, Neal A Chatterjee, Muthiah Vaduganathan, et al.
JAMA
|
May 29, 2024
Revisiting Race and the Benefit of RAS Blockade in Heart Failure: A Meta-Analysis of Randomized Clinical Trials
Li Shen, Matthew M Y Lee, Pardeep S Jhund, et al.
Page
of 188